VBI Vaccines rises as COVID-19 drug shows promise

VBI Vaccines

05/04/2022 13:33

** Shares of VBI Vaccines Inc  VBIV.O  rise 2.2% to $1.85
premarket
    ** Co says early-stage data from a drug to treat the beta
variant of the COVID-19 virus, shows encouraging ability to
boost and broaden immune response  urn:newsml:reuters.com:*:nFWN2W3133
    ** Expects to initiate early stage study of VBI-2901, a
pan-coronavirus candidate, in summer 
    ** VBIV is set to extend gains to third straight session 
    ** Stock down ~23% YTD, as of last close
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))